Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Denali Therapeutics Inc.

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via Globe NewsWire
Tickers DNLI
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
From Denali Therapeutics Inc.
Via Globe NewsWire
Tickers DNLI
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
From Denali Therapeutics Inc.
Via Globe NewsWire
Tickers DNLI
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
From Denali Therapeutics Inc.
Via Globe NewsWire
Tickers DNLI
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
From Denali Therapeutics Inc.
Via Globe NewsWire
Tickers DNLI
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
From Denali Therapeutics Inc.
Via Globe NewsWire
Tickers DNLI
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via Globe NewsWire
Tickers DNLI
Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN
From Denali Therapeutics Inc.
Via Globe NewsWire
Tickers DNLI
Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Denali Therapeutics Inc.
Via Globe NewsWire
Tickers DNLI
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
From Denali Therapeutics Inc.
Via Globe NewsWire
Tickers DNLI
Denali Therapeutics Announces Proposed Offering of Common Stock
From Denali Therapeutics Inc.
Via Globe NewsWire
Tickers DNLI
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
From Denali Therapeutics Inc.
Via Globe NewsWire
Tickers BIIB DNLI
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.